SCHEDULE 13G/A: Perceptive Advisors and Joseph Edelman Disclose 7.9% Stake in Amylyx Pharmaceuticals

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 7.9% beneficial ownership stake in Amylyx Pharmaceuticals, Inc., totaling 6,774,348 shares.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Amylyx Pharmaceuticals, Inc.
• The Reporting Persons collectively beneficially own 6,774,348 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
• This ownership represents 7.9% of the Issuer's outstanding Common Stock, based on 85,688,365 shares reported by Amylyx Pharmaceuticals, Inc. in its prospectus filed on January 10, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds all 6,774,348 shares.
• Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors LLC.
• The Reporting Persons share both voting and dispositive power over all 6,774,348 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a standard disclosure of beneficial ownership by a significant institutional investor. While not directly impacting company operations, it provides transparency and can be viewed as a neutral to slightly positive signal of institutional confidence.

Positives

• The disclosure of a significant stake by a specialized institutional investor like Perceptive Advisors may be viewed as a vote of confidence in Amylyx Pharmaceuticals' long-term prospects.
• Increased transparency regarding the ownership structure of a notable institutional holder.

Negatives

• No specific negative financial or operational information is disclosed in this beneficial ownership report, as its primary purpose is to report ownership.

Risks

• The filing does not detail specific operational or financial risks of Amylyx Pharmaceuticals, as its primary purpose is to report beneficial ownership.
• The Reporting Persons have certified that the securities were not acquired for the purpose of changing or influencing control of the issuer, mitigating immediate governance risks from this specific filing.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Amylyx Pharmaceuticals' future outlook or operational performance.

Management Comments

• The reporting persons certified that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

Perceptive Advisors is a prominent investment firm specializing in the life sciences sector. Their significant stake in Amylyx Pharmaceuticals, a biotechnology company, aligns with their established investment strategy within the pharmaceutical and biotech industry, indicating continued institutional interest in the sector.

Comparison to Industry Standards

• This filing is a disclosure of beneficial ownership and does not provide specific financial or operational data for direct comparison to industry standards or competitors' performance.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception.
• Management: Awareness of a large, potentially influential shareholder, though the filing states no intent to influence control.

Next Steps

• The document does not specify future actions, events, or milestones for Amylyx Pharmaceuticals or the reporting persons beyond the continued beneficial ownership.

Key Dates

Keywords

Amylyx Pharmaceuticals, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, beneficial ownership, Schedule 13G, common stock, institutional investment, biotechnology, pharmaceuticals